Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NRSN
stocks logo

NRSN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.200
sliders
Low
9.00
Averages
9.00
High
9.00
Current: 1.200
sliders
Low
9.00
Averages
9.00
High
9.00
Noble Capital
Robert LeBoyer
initiated
$9
2025-10-14
Reason
Noble Capital
Robert LeBoyer
Price Target
$9
2025-10-14
initiated
Reason
Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense with an Outperform rating and $9 price target. Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer's disease showed "promising data."
D. Boral Capital
Jason Kolbert
Buy
initiated
$14
2025-05-12
Reason
D. Boral Capital
Jason Kolbert
Price Target
$14
2025-05-12
initiated
Buy
Reason
Maxim Group
Naz Rahman
Strong Buy
to
Hold
Downgrades
n/a
2024-12-16
Reason
Maxim Group
Naz Rahman
Price Target
n/a
2024-12-16
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN.O) is -3.91, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess Neurosense Therapeutics Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.08
Current PE
-3.91
Overvalued PE
-1.08
Undervalued PE
-3.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.89
Current PS
0.00
Overvalued PS
44.76
Undervalued PS
-22.99
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NRSN News & Events

Events Timeline

(ET)
2025-11-24
10:01:21
NeuroSense Announces FDA Approval to Begin Phase 3 Trial of PrimeC for ALS
select
2025-08-20 (ET)
2025-08-20
09:48:47
NeuroSense reveals that 20% of ALS patients in Phase 2a study continue treatment with PrimeC
select
link
2025-01-06 (ET)
2025-01-06
08:06:45
NeuroSense regains Nasdaq compliance
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04PRnewswire
NeuroSense Resumes Regulatory Progress for PrimeC in Canada, Anticipates NDS Submission by Mid-2026
  • Regulatory Progress: Following productive discussions with Health Canada, NeuroSense confirmed the resumption of regulatory advancement for PrimeC in amyotrophic lateral sclerosis (ALS), with a pre-NDS meeting anticipated in April 2026, potentially leading to an NDS submission by mid-2026, significantly enhancing the company's market position in ALS treatment.
  • Clinical Data Support: Recent additional clinical data generated by the company will support the NDS submission, indicating an increasing R&D capability in ALS treatment, which may attract more investor interest and boost stock prices.
  • Market Demand: Over 5,000 people are diagnosed with ALS annually in the U.S., with a projected 24% increase in cases by 2040, providing substantial market potential for NeuroSense's PrimeC to address unmet medical needs.
  • Innovative Drug: PrimeC is a novel extended-release oral formulation combining two FDA-approved drugs, targeting multiple key mechanisms of ALS and Alzheimer's Disease; if successfully launched, it will offer new treatment options for patients and enhance the company's competitiveness in the biotechnology sector.
[object Object]
Preview
4.0
11-24Benzinga
D. Boral Capital Reiterates Buy Rating for NeuroSense Therapeutics with $14 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.

  • Market Winning Tools: Traders utilize Benzinga Pro's tools and intelligence to improve their trading strategies and outcomes.

[object Object]
Preview
9.0
11-24PRnewswire
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

  • FDA Approval for Clinical Trial: NeuroSense Therapeutics has received FDA authorization to initiate a pivotal Phase 3 clinical trial for its lead drug candidate, PrimeC, aimed at treating amyotrophic lateral sclerosis (ALS).

  • Trial Design and Goals: The PARAGON trial will involve 300 ALS patients and is designed to evaluate the efficacy and safety of PrimeC over a 12-month period, with an adaptive design allowing for interim analyses.

  • Significance of PrimeC: PrimeC is a novel oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, targeting multiple mechanisms involved in ALS and Alzheimer's Disease.

  • Commitment to ALS Treatment: NeuroSense emphasizes its dedication to addressing the significant unmet medical needs of ALS patients and plans to share further details about the trial in an upcoming investor webinar.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neurosense Therapeutics Ltd (NRSN) stock price today?

The current price of NRSN is 1.2 USD — it has decreased -2.44 % in the last trading day.

arrow icon

What is Neurosense Therapeutics Ltd (NRSN)'s business?

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

arrow icon

What is the price predicton of NRSN Stock?

Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neurosense Therapeutics Ltd (NRSN)'s revenue for the last quarter?

Neurosense Therapeutics Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Neurosense Therapeutics Ltd (NRSN)'s earnings per share (EPS) for the last quarter?

Neurosense Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Neurosense Therapeutics Ltd (NRSN)'s fundamentals?

The market is revising No Change the revenue expectations for NeuroSense Therapeutics Ltd. (NRSN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 1.69%.
arrow icon

How many employees does Neurosense Therapeutics Ltd (NRSN). have?

Neurosense Therapeutics Ltd (NRSN) has 15 emplpoyees as of December 05 2025.

arrow icon

What is Neurosense Therapeutics Ltd (NRSN) market cap?

Today NRSN has the market capitalization of 35.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free